App-Quantinova.ai

DEVELOPMENT OF ANTIBODY RESPONSE TO SARS-COV-2 FOLLOWING ASYMPTOMATIC INFECTION IN PATIENTS WITH PLASMA CELL DISORDERS ON IMMUNOMODULATORY THERAPY

Wei Yee Chan - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

COGNITIVE IMPAIRMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA

Camelia Vladescu - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

N/A

EFFECTIVENESS AND SAFETY OF IXAZOMIB-BASED THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) OUTSIDE OF A CLINICAL TRIAL: FINAL ANALYSIS OF THE ‘USE VIA EARLY ACCESS TO IXAZOMIB’ (UVEA IXA) STUDY

Heinz Ludwig - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Lenalidomide

COMPARISON OF VENETOCLAX INPATIENT AND OUTPATIENT RAMP-UP STRATEGIES FOR CLL. UK MULTICENTRE RESTROSPECTIVE STUDY

Roco Figueroa Mora - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Rasburicase

QUANTIFYING THE HEALTHCARE RESOURCE USE AND CLINICAL OUTCOMES OF PATIENTS WITH BETA THALASSAEMIA IN ENGLAND

James Farrell - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

CLINICAL BENEFIT OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB IN JAK INHIBITOR TREATMENT NAÏVE MYELOFIBROSIS PATIENTS: INTERIM EFFICACY SUBGROUP ANALYSIS FROM ARM 3 OF MANIFEST PH2 STUDY

Marina Kremyanskaya - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): 1-YEAR INTERIM RESULTS OF THE PHASE 3 CARDINAL STUDY LONG-TERM FOLLOW-UP

Alexander Rth - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

ACTIVATE: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MITAPIVAT IN ADULTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED

Hanny Al-Samkari - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Pyruvate kinase (PK) deficiency

AG348

ACUTE RESISTANCE TO BET INHIBITORS REMODELS COMPENSATORY TRANSCRIPTIONAL PROGRAMMES VIA P300 CO-ACTIVATION

Daniel Sasca - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

DMSO

DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN PATIENTS OLDER THAN 65 YEARS: ANALYSIS OF 3 YEAR REAL WORLD DATA OF PRACTICE PATTERNS AND OUTCOMES IN ENGLAND

Luke Hounsome - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)

David Ross - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Essential thrombocythemia

Anagrelide hydrochloride

TREATMENT SELECTION IN CML: EFFECT OF ONLINE EDUCATION ON CLINICIAN KNOWLEDGE AND CONFIDENCE

Amanda Taylor - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Ponatinib

ESTIMATED HOSPITALIZATION-RELATED COSTS WITH ORAL AZACITIDINE (ORAL-AZA) VS PLACEBO (PBO) FOR REMISSION MAINTENANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN SPAIN AND THE UNITED KINGDOM (UK)

Christopher Pocock - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Vidaza

MIRNA EXPRESSION IN ADULT ACUTE MYELOID LEUKAEMIA: BIOMARKERS FOR RISK SUBGROUPS?

Pinar Uysal-Onganer - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

SURVIVAL AMONG OLDER PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA TREATED WITH SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE (XVD) IN THE BOSTON STUDY

Thierry Facon - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

CLINICAL OUTCOMES IN PATIENTS RELAPSED/REFRACTORY AFTER ≥ 2 PRIOR LINES OF THERAPY FOR FOLLICULAR LYMPHOMA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

Steve Kanters - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

N/A

FIRST RESULTS OF A HEAD-TO-HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA

Peter Hillmen - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

ACP-196

EUROPEAN GUIDELINES AND REAL-WORLD EVIDENCE OF MAINTENANCE TREATMENTS FOR ADULTS WITH ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION

Moez Ahmed - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

THROMBOELASTOMETRY AND CONVENTIONAL COAGULATION TESTS AS PREDICTORS OF PROGRESSION TO CRITICAL PHASE IN PATIENTS IN THE FEBRILE PHASE OF DENGUE FEVER: A PRELIMINARY PROSPECTIVE CASE CONTROL STUDY

Ahalyaa Sivashangar - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Dengue fever

Fibrinogen (IV)

EXCELLENT COMPARABLE OUTCOMES OF HAPLO-HSCT IN HIGH RISK MYELOID MALIGNANCIES USING MYELOABLATIVE OR REDUCED INTENSITY CONDITIONING WITH LOW RISK OF CGVHD IN RECIPIENTS OF PERIPHERAL BLOOD STEM CELL

Daniele Avenoso - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

Cyclophosphamide

Filters

45280 Abstracts